George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Turnaround just begun,
Revenue follows on shortly afterwards.
Its 4p not 40p , mkcap less than 4m
I’ll be reminding you in the coming weeks months,
I’m interested in your views.
NO REVENUE..... -34.59 (-89.84%)past year..... True facts and no Jam....
Credit
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the receipt of an R&D tax credit from HMRC in respect of the financial year ended 31 March 2023, relating to work performed on the development and optimization of the OptiMAL® platform, as well as other R&D projects in bioinformatics, antigen design and cell culture. The value of the tax credit is in line with expectations at almost £280k, which reflects the Company's continued investment in R&D projects that maintain Fusion at the forefront of technology in the antibody market. The technologies have been well received by partners and potential partners with the OptiMAL® platform notably undergoing validation through an agreement with the National Cancer Institute in the USA. Fusion will maximise the impact of the tax credit with the generation of revenue streams from the R&D projects that were supported.
Adrian Kinkaid, CEO of Fusion, said: "The R&D tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion. We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."
NO revenue, 10s of millions of PLACING shares, BoDs paid in shares, projects DELAYED, stringent cost cutting across all of the company, contracts with ZERO revenue.... Theres been next to no revenue since they fund raised at an enormous 84% DISCOUNT May 2023... You think that shouts out strong buy...🤣🤡🤣🤡🤣🤡
Just the beginning of the turnaround and already this year we’ve seen two contracts and a collaboration , partnership with the NCI, National Cancer institute in the US.
Some going in Less than three months.
This year is going to be transformational for the company and for us shareholders .
Revenue will follow not far behind.
Strong buy 100 percent.
Where did you see that enable significant cash flow from royalty’s line Chris?
Not baffling at all. There is no revenue and 10s of millions of placing shares in the background and there has been for a few months. Any news will be heavily sold into, the slightest rise and wallop sellers. This needs contracts with revenue to get rid of the overhang until then under 4p, deal with it peeps... Strong Sell....
Royalties are the best option to bring in much higher revenues,
Our tech will be in very high demand globally, expect many many new contracts in all areas. Gla
To enable the Company to gain significant cash flows from new royalty payments and significant cost savings
No "Earnings "from this contract Just Royalties in the future
I too think it is an absolute bargain at this price, but our view doesn't really matter only that of the market.
Pump up the volume, pump up the volume.
Get those shares moved from those that don't want to hold them to those that do.
LOTM
If we stayed blue and rise towards 5 there would have been lot attention here, this is defo a bargain, I still want to see earnings figures from this contract
Donotpanic,
Personally I'd much rather see volume at 7M+ traded & lots of new longer term shareholders coming on board than the share price being up on the day.
Looks like someone just left the company as only 28 employees currently down from 29 earlier today & friday. Although they still have like 3 jobs to fill.
LOTM
Not much at 4 left now, could be back to blue
Hi livinhope,
Going by what's said in the announcement & then linking it to a post by the company on LinkedIN about 5 days ago.
LOTM
Its either for cats or dogs I'd say.????
Why?
I'd say NO as its definitely not for human's. Its either for cats or dogs I'd say.
LOTM
Any of these?
Something big as they stated it’s a leading global provider of antibodies.
https://blog.citeab.com/who-are-the-leading-research-antibody-market-suppliers/
Any ideas who the company is that’s a leading global supplier of antibodies.
The royalties from this could be worth 10s of millions if global demand is achieved.
Hi gtc1507,
Not really, no way of investors being able to put a value on it (this piece of news).
Company has to do a much better PR job than its doing, Academics are often not good at explaining things in a meaningful way to investors.
The announcement headline isn't eye catching & its not caught investors imagination otherwise you'd have seen a lot more trades going through, even if they were for relatively small amounts of shares.
Company clearly needs to expand its investor base. It does that by investor engagement, which I sadly doubt we'll see.
Proactive interview & an updated Presentation, might help to start the ball rolling in that regard, because as everyone can see there is no buying interest other than from those already onboard.
LOTM
Truly baffling response to this great news!!
I think so, too.
They are turning things around and more good news to come too.
That is good buy Chris, from 4.38 to under 4 to buy is worth it, this will bounce hard, no reason for the drop
Took 2 x 50k
Ha